Oral VK2735 is strategically positioned to become a best-in-class oral GLP-1 therapy, with the Phase 2 trial data readout in H2 2025 serving as a critical catalyst. Phase 1 data for VK2735 ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7 ...

In the second quarter of 2025, the business intends to start Phase 3 studies for their subcutaneous obesity therapy, VK2735. Targeting metabolic and endocrine diseases, the San Diego-based ...

Viking Therapeutics ( VKTX, Financials) reported its fourth-quarter and full-year 2024 financial results, highlighting progress in its obesity drug pipeline and a strong cash position of $903 million.

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25. VK2735 is a wholly owned dual agonist of the glucagon like peptide-1, or GLP-1 receptor, and the glucose ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

In contrast, Viking Therapeutics' shares experienced modest gains. Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only ...